Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.59 |
| ▸ | LSS | P48449 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 5/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11936113 | 0.84 | PPARA (0.56) | PPARAPPARGMEN1KMT2A | |
| SCHEMBL10114512 | 0.84 | EPHX2 (0.64) | PPARAEPHX2NR1H4LSSPPARG | |
| SCHEMBL12882064 | 0.84 | EPHX2 (0.62) | PPARAEPHX2NR1H4PPARGMAPT | |
| SCHEMBL13565993 | 0.83 | PPARA (0.55) | PPARA | |
| SCHEMBL10116572 | 0.83 | TRPV1 (0.62) | PPARAMAPTLMNA | |
| SCHEMBL5307831 | 0.77 | PPARA (0.51) | PPARAEPHX2NR1H4LMNA | |
| SCHEMBL13947580 | 0.77 | LSS (0.72) | PPARAEPHX2NR1H4LSSPPARG | |
| SCHEMBL14424840 | 0.77 | LSS (0.57) | PPARAEPHX2NR1H4LSSPPARG | |
| SCHEMBL12010898 | 0.77 | MAPT (0.80) | PPARALSSMAPK14NAMPTMAPT | |
| SCHEMBL6572354 | 0.76 | HDAC6 (0.72) | PPARAEPHX2LSSPPARGMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | PPARA 1501/4885EPHX2 2158/4885NR1H4 283/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | PPARA 1639/4885EPHX2 2527/4885NR1H4 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.